Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSNNASDAQ:KRONNASDAQ:PRLDNASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsKRONKronos Bio$0.88-0.8%$0.78$0.65▼$1.60$53.60M1.63362,094 shs2.14 million shsPRLDPrelude Therapeutics$0.87-6.7%$0.89$0.61▼$6.80$48.84M1.25281,041 shs153,652 shsXCURExicure$7.65-8.1%$10.39$1.44▼$36.00$48.34M3.71556,182 shs9,218 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSNImunon0.00%0.00%0.00%0.00%0.00%KRONKronos Bio-0.28%-0.56%+29.92%-1.13%-14.90%PRLDPrelude Therapeutics-4.76%-14.12%+5.02%+25.81%-76.40%XCURExicure-5.78%-15.87%-17.30%-34.82%+2,456.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AKRONKronos Bio3.3201 of 5 stars3.23.00.00.01.94.21.3PRLDPrelude Therapeutics2.9789 of 5 stars3.22.00.00.00.05.00.6XCURExicure1.8512 of 5 stars0.04.00.04.73.20.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSNImunon 0.00N/AN/AN/AKRONKronos Bio 2.33Hold$1.6385.08% UpsidePRLDPrelude Therapeutics 2.33Hold$4.00362.43% UpsideXCURExicure 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CLSN, PRLD, XCUR, and KRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/29/2025PRLDPrelude TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$4.00 ➝ $4.004/8/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSNImunon$500K0.00N/AN/A$9.66 per share0.00KRONKronos Bio$9.85M5.44N/AN/A$1.45 per share0.61PRLDPrelude Therapeutics$7M6.98N/AN/A$2.39 per share0.36XCURExicure$500K96.68N/AN/A$1.12 per share6.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AKRONKronos Bio-$86.08M-$1.07N/AN/AN/A-701.53%-64.22%-47.17%8/6/2025 (Estimated)PRLDPrelude Therapeutics-$127.17M-$1.69N/AN/AN/AN/A-89.18%-69.26%8/11/2025 (Estimated)XCURExicure-$9.70M-$4.81N/A∞N/AN/A-319.72%-82.41%8/11/2025 (Estimated)Latest CLSN, PRLD, XCUR, and KRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025PRLDPrelude Therapeutics-$0.47-$0.42+$0.05-$0.42N/AN/A3/18/2025Q4 2024KRONKronos Bio-$0.30-$0.43-$0.13-$0.43$1.00 million$2.27 million3/18/2025Q4 2024XCURExicureN/A-$3.39N/A-$3.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSNImunonN/AN/AN/AN/AN/AKRONKronos BioN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSNImunon0.136.526.52KRONKronos BioN/A12.9312.93PRLDPrelude TherapeuticsN/A5.185.18XCURExicureN/A4.454.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSNImunon12.97%KRONKronos Bio64.09%PRLDPrelude Therapeutics79.72%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipCLSNImunon4.66%KRONKronos Bio24.40%PRLDPrelude Therapeutics63.90%XCURExicure8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSNImunon277.10 million6.77 millionOptionableKRONKronos Bio10061.05 million46.16 millionOptionablePRLDPrelude Therapeutics12056.46 million20.38 millionOptionableXCURExicure506.32 million5.79 millionNot OptionableCLSN, PRLD, XCUR, and KRON HeadlinesRecent News About These CompaniesExicure (NASDAQ:XCUR) Stock Price Down 5.8% - Here's WhyJune 18 at 1:51 AM | marketbeat.comExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QMay 28, 2025 | businesswire.comExicure (NASDAQ:XCUR) Trading Down 4.5% - Here's WhyMay 28, 2025 | marketbeat.comWhy Exicure Inc. (XCUR) Soared on MondayApril 22, 2025 | msn.comExicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myelomaApril 16, 2025 | pharmabiz.comExicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100April 15, 2025 | pharmabiz.comExicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple MyelomaApril 14, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...April 11, 2025 | gurufocus.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | investing.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | businesswire.comWednesday’s Insider Moves: Top Buys and Sells in US StocksMarch 27, 2025 | investing.comExicure, Inc. Reports Full Year 2024 Financial ResultsMarch 18, 2025 | gurufocus.comExicure secures Australian patent for cancer treatmentMarch 15, 2025 | investing.comExicure announces issuance of new patent in AustraliaMarch 15, 2025 | markets.businessinsider.comExicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in AustraliaMarch 13, 2025 | gurufocus.comKuehn Law Encourages Investors of Exicure, Inc. to Contact Law FirmJanuary 27, 2025 | markets.businessinsider.comExicure announces purchase agreement with GPCR TherapeuticsJanuary 24, 2025 | markets.businessinsider.comCORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.January 23, 2025 | businesswire.comExicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.January 22, 2025 | businesswire.comWhen the Price of (XCUR) Talks, People ListenJanuary 21, 2025 | news.stocktradersdaily.comWhen (XCUR) Moves Investors should ListenJanuary 11, 2025 | news.stocktradersdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLSN, PRLD, XCUR, and KRON Company DescriptionsImunon NASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Kronos Bio NASDAQ:KRON$0.88 -0.01 (-0.79%) Closing price 03:58 PM EasternExtended Trading$0.88 0.00 (0.00%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.Prelude Therapeutics NASDAQ:PRLD$0.86 -0.06 (-6.74%) Closing price 03:59 PM EasternExtended Trading$0.86 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Exicure NASDAQ:XCUR$7.65 -0.67 (-8.05%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Microsoft-OpenAI Rift May Cap Stock Upside Potential Jabil Stock Hits Highs on AI Tailwinds and Strong Buybacks Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
